ALNAPHARM

Alnapharm is a German biotechnology company focused on developing innovative treatments for degenerative eye diseases, particularly dry Age-related Macular Degeneration (dry AMD) and Stargardt disease. The company's lead candidate, Alna-Retinol, is a patented formulation of Vitamin A designed to stabilize the visual cycle and prevent the accumulation of toxic lipofuscin in the retina. Headquartered in Hamburg, Alnapharm leverages its expertise in micronutrient pharmacology to address significant unmet needs in ophthalmology. The company has conducted clinical studies to evaluate the efficacy and safety of its high-dose retinol therapy in slowing disease progression. In addition to its pharmaceutical pipeline, Alnapharm offers a range of specialized nutritional supplements, such as Alna-Q10 and Alna-Zink, to support overall ocular health.